State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang & Key Laboratory of Endemic and Ethnic Diseases, Ministry of Education, Guizhou Medical University, Guiyang, China; The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academic of Sciences, Guiyang, China.
Key Laboratory of Modern Pathogen Biology and Characteristics, School of Basic Medicine, Guizhou Medical University, Guiyang, China.
Phytomedicine. 2023 Jun;114:154810. doi: 10.1016/j.phymed.2023.154810. Epub 2023 Apr 6.
Breast cancer is the most prevalent cancer worldwide, with high morbidity and mortality. Despite great advances in the therapeutic strategies, the survival rate in the past decades of patients with breast cancer remains unsatisfactory. Growing evidence has demonstrated that Curcumae Rhizoma, called Ezhu in Chinese, showed various pharmacological properties, including anti-bacterial, anti-oxidant, anti-inflammatory and anti-tumor activities. It has been widely used in Chinese medicine to treat many types of human cancer.
To comprehensively summarize and analyze the effects of active substances in Curcumae Rhizoma on breast cancer malignant phenotypes and the underlying mechanisms, as well as discuss its medicinal value and future perspectives.
We used "Curcumae Rhizoma" or the name of crude extracts and bioactive components in Curcumae Rhizoma in combination with "breast cancer" as key words. Studies focusing on their anti-breast cancer activities and mechanisms of action were extracted from Pubmed, Web of Science and CNKI databases up to October 2022. The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guideline was followed.
Crude extracts and 7 main bioactive phytochemicals (curcumol, β-elemene, furanodiene, furanodienone, germacrone, curdione and curcumin) isolated from Curcumae Rhizoma have shown many anti-breast cancer pharmacological properties, including inhibiting cell proliferation, migration, invasion and stemness, reversing chemoresistance, and inducing cell apoptosis, cycle arrest and ferroptosis. The mechanisms of action were involved in regulating MAPK, PI3K/AKT and NF-κB signaling pathways. In vivo and clinical studies demonstrated that these compounds exhibited high anti-tumor efficacy and safety against breast cancer.
These findings provide strong evidence that Curcumae Rhizoma acts as a rich source of phytochemicals and has robust anti-breast cancer properties.
乳腺癌是全球最常见的癌症,发病率和死亡率都很高。尽管在治疗策略方面取得了巨大进展,但过去几十年乳腺癌患者的生存率仍然不尽人意。越来越多的证据表明,莪术,又称莪术,具有多种药理作用,包括抗菌、抗氧化、抗炎和抗肿瘤活性。它已被广泛应用于中药治疗多种人类癌症。
全面总结和分析莪术中的活性物质对乳腺癌恶性表型的影响及其作用机制,并探讨其药用价值和未来前景。
我们使用“莪术”或莪术的粗提物和生物活性成分的名称与“乳腺癌”作为关键词,从 Pubmed、Web of Science 和 CNKI 数据库中提取了关注其抗乳腺癌活性及其作用机制的研究。截至 2022 年 10 月,遵循系统评价和荟萃分析的首选报告项目(PRISMA)2020 指南。
莪术的粗提物和 7 种主要生物活性植物化学物质(莪术醇、β-榄香烯、呋喃二烯、呋喃二烯酮、莪术烯、莪术酮和姜黄素)已显示出许多抗乳腺癌的药理作用,包括抑制细胞增殖、迁移、侵袭和干性,逆转化疗耐药性,诱导细胞凋亡、细胞周期停滞和铁死亡。作用机制涉及调节 MAPK、PI3K/AKT 和 NF-κB 信号通路。体内和临床研究表明,这些化合物对乳腺癌具有很高的抗肿瘤疗效和安全性。
这些发现为莪术作为植物化学物质的丰富来源和强大的抗乳腺癌特性提供了有力证据。